ylliX - Online Advertising Network
Press Release

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) — atai Life Sciences  (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders.

...read full article on GlobeNewsWire

ylliX - Online Advertising Network